Esperion Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Esperion Therapeutics generated cash of -$135,487,000, which is more than the previous year. Cash used in financing activities reached the amount of $50,460,000 last year. Net change in cash is therefore -$42,527,000.
Cash Flow
| 2014 | -32.02M | -36.59M | 97.12M |
|---|---|---|---|
| 2015 | -38.15M | -160.06M | 190.52M |
| 2016 | -47.73M | 10.11M | -1.55M |
| 2017 | -131.30M | -35.85M | 163.45M |
| 2018 | -148.63M | 140.44M | 10.69M |
| 2019 | -70.34M | 64.23M | 136.19M |
| 2020 | -85.17M | 21.35M | 201.72M |
| 2021 | -263.80M | -50.48M | 268.22M |
| 2022 | -174.82M | 8.10M | 32.60M |
| 2023 | -135.48M | 42.5M | 50.46M |
ESPR Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 124.77M | 258.89M | 304.96M | 167.05M | 36.97M | 34.46M | 38.16M | 77.33M | 85.03M | 56.53M |
Operating activities | ||||||||||
Net income | -209.24M | -233.65M | -269.10M | -143.55M | -97.16M | -201.81M | -166.98M | -74.97M | -49.78M | -36.37M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 164K | 500K | 612K | 547K | 319K | 265K | 258K | 252K | 236K | 160K |
Stock-based compensation expense | 11.95M | 15.21M | 24.30M | 28.38M | 25.88M | 0 | 18.60M | 15.95M | 12.72M | 3.67M |
| Deferred income tax benefit | 11.95M | 15.21M | 24.30M | 28.38M | 25.88M | 0 | 18.60M | 15.95M | 12.72M | 3.67M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -14.76M | -10.79M | -10.54M | -10.74M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -30.42M | -807K | -18.25M | -16.13M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 8.67M | 5.60M | -34.09M | 23.10M | -16.05M | 24.44M | 15.75M | 3.88M | -1.33M | -299K |
Cash generated by operating activities | -135.48M | -174.82M | -263.80M | -85.17M | -70.34M | -148.63M | -131.30M | -47.73M | -38.15M | -32.02M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -59.89M | -50.48M | -4.42M | -34.32M | -25.48M | -219.57M | -197.23M | -280.55M | -48.08M |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -13.36M | -953K | -151K | -19K | -94K | -325K | -873K |
Acquisitions Net | 0 | 0 | 0 | 12.5M | -65.18M | 0 | 0 | 0 | 24K | 0 |
Cash generated by investing activities | 42.5M | 8.10M | -50.48M | 21.35M | 64.23M | 140.44M | -35.85M | 10.11M | -160.06M | -36.59M |
Financing activities | ||||||||||
Common Stock Issued | 56.87M | 90.84M | 218.68M | 6.63M | 11.77M | 0 | 164M | 0 | 189.98M | 91.73M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -55M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -755K | -296.09M | 0 | -1.04M | -1.70M | -1.60M | -638K | 0 |
Cash used in financing activities | 50.46M | 32.60M | 268.22M | 201.72M | 136.19M | 10.69M | 163.45M | -1.55M | 190.52M | 97.12M |
Net Change In Cash | -42.52M | -134.11M | -46.07M | 137.90M | 130.08M | 2.50M | -3.69M | -39.17M | -7.70M | 28.50M |
Cash at end of period | 82.24M | 124.77M | 258.89M | 304.96M | 167.05M | 36.97M | 34.46M | 38.16M | 77.33M | 85.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |